Roche laid out its ambitions in the social part of its environmental, social and governance (ESG) strategy on Monday centered on access to its drugs and diagnostics.
The Roche inaugural ESG. More companies are publishing reports and holding calls to outline climate, societal, diversity, and even pricing goals as investors clamor for details amid surging interest in ESG commitments.
RBC Capital Markets forecast last year that the pharma sector is poised to raise its historically poor ratings in the booming ESG investment market – now more than $ 820 million in assets under management. Covid pandemic reputation gains, along with declining litigation, improving drug pricing accountability and more management involvement in ESG issues
On Monday, Roche executives set its targets – in some cases recharging or updating them – while also pointing out what has been accomplished when it comes to accessing its meds and diagnostics. Bruno Eschli, Roche’s head of investor relations, said.
“Access is not a topic specific to just one geography, but rather every country has its own special challenges,” he said.
For the upper-middle and high-income countries, for instance, increasing health costs, there is no shortage of healthcare infrastructure , low awareness and diagnoses rates, and general economic pressure.
While the Covid-19 pandemic worsened issues for both groups, Roche sees some bright spots. In the lower income countries, along with the adoption of telehealth and cross-country collaborations in lower income countries.
Separating its diagnostic and pharmaceutical divisions, Roche’s executives are guaranteed top-level pharma goals by 2030, and double-low- and middle-income patient enrollment by 2026, and in diagnostics to double-patient access by 2030.
Along with its accomplishments for 2021, Roche listed 16.4 million people treated with Roche meds, 27 billion Roche diagnostic tests conducted, 80 new molecules in development and its representation of 44% women across its management teams.
Michael Oberreiter, Roche head of the global pandemic problem and in particular its impact on global health coverage, which does not create financial hardship. Today, 50% of the world’s population lack access to essential healthcare, he said, while 100 million enter into poverty because of out-of-pocket health care costs.
“We’re quite aware that in the eye of the beholder,” he said. “We don’t claim and know we don’t own the definition. But what we think is our own responsibility and the need to raise awareness of the different dimensions of value – its societal value, HCP value, and patient and caregiver value and have a robust dialogue with all stakeholders. ”